Search

Displaying results 401 - 410 of 2955 in total
  1. Drug

    Hydrochlorothiazide

    go.drugbank.com/drugs/DB00999
    ApprovedInvestigationalVet approved

    [L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959.[L8444]

    Mixtures: OLMETEC PLUS 20/25MG FTA, OLMETEC PLUS 20/25MG FTAProducts: BENAZEPRIL IDROCLOROTIAZIDE EG, Nu-hydro
  2. Drug

    Benzoyl peroxide

    go.drugbank.com/drugs/DB09096
    ApprovedInvestigational

    [A234059,A234064,A234069] Benzoyl peroxide, in combination with erythromycin, was granted FDA approval on 26 October 1984.[L33264]

    Products: NO + ACNE CREMA PARA EL ACNE NON GRAS ®, Clinique Acne Solutions All-over Clearing Treatment
  3. Drug

    Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen

    go.drugbank.com/drugs/DB16709
    Approved

    The product does not remain permanently engrafted, instead being replaced by the patient's own cells over time, which can reduce or even eliminate the need for autografting. … [L35505] Stratagraft was in the early stages of development as far back as 2009[A237275] and was granted full FDA approval in June 2021.[L35525]

  4. Drug

    Sugammadex

    go.drugbank.com/drugs/DB06206
    ApprovedInvestigational

    Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. … Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.

    Products: SUGAMMADEX EG
  5. Drug

    Fluticasone propionate

    go.drugbank.com/drugs/DB00588
    ApprovedInvestigational

    Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. … These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990[L5962].

    Mixtures: SALFLUTIN 50/100UG 60 ED, SALFLUTIN 50/250UG 60 EDProducts: FLUTIDE FORTE 500 DISKU ED, FLUTIDE MITE 100 DISKUS ED
  6. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [L47122] In June 2023, Rozanolixizumab-noli was approved by the FDA under Priority Review for the treatment of adult patients with generalized myasthenia gravis who are positive for the anti-acetylcholine … [A260192] As a result, the main clinical manifestation of myasthenia gravis is easily fatigable or persistent muscle weakness.

  7. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    [A187991] Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment … Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway.

  8. Drug

    Zilucoplan

    go.drugbank.com/drugs/DB15636
    ApprovedInvestigational

    [A261841] On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of generalized myasthenia gravis.

  9. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    [L39710] Ravulizumab is also used to treat myasthenia gravis. … [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.

  10. Drug

    Ursodeoxycholic acid

    go.drugbank.com/drugs/DB01586
    ApprovedInvestigational

    [A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary biliary cirrhosis in 1996.

    Products: Nra-ursodiol, ACIDO URSODESOSSICOLICO EG